The two-year rodent bioassay is one of several tests that are widely used by governmental regulatory agencies as well as pharmaceutical and chemical companies to determine the carcinogenic potential of chemicals or environmental agents where human exposure is anticipated. That this assay has remained relatively unchanged for the last 25 years is a testament to the power of this approach to identify carcinogens and thus to minimize human exposure. However, there has long been controversy over the specificity and relevance of the rodent bioassay as well as its high cost in terms of time, expense, and numbers of mice. Much discussion has been generated in recent years over how to improve the 2-year rodent bioassay for more accurate and faster detection of potential human carcinogens. Here, we argue that the use of p27 Kip1 (Cdkn1b) knockout mouse for carcinogen screening may solve several shortcomings inherent in the conventional bioassay while preserving its best quality, that is, protecting public health by providing reliable in vivo information on the potential of chemicals to cause cancer.
HISTORY OF THE 2-YEAR RODENT BIOASSAY
The history of the conventional two-year rodent bioassay dates to 1962 when the National Cancer Institute (NCI) began carcinogen screening programs in response to increasing public concern over environmental causes of cancer. According to the International Conference for Harmonization (ICH) S1A guidelines, carcinogenicity testing is required when human exposure to the chemical is expected to last for 6 months or more and/or when there is cause for concern over the carcinogenic potential of the chemical (47) . The conventional bioassay involves treating groups of 50 male and 50 female animals with the chemical in a 2-year study. Frequently several doses are used, ranging from high doses to those that are similar to the level of human exposure. The animals are examined postmortem for tumor incidence and other pathologic changes and statistical analysis determines whether the tumor incidence in treated animals is significantly higher than in untreated control animals.
The primary argument in favor of the 2-year bioassay has remained the same for the last 40 years. Simply, the difficulty in predicting whether a given chemical is carcinogenic and the supreme importance of protecting public health argues for the use of an in vivo assay. Current in vitro assays do not detect all possible human carcinogens. While several highly characterized and accurate in vitro assays [most importantly, the Ames test using Salmonella (36) ] for genotoxic carcinogens exist, the incompletely understood mechanisms by which nongenotoxic carcinogens function complicates the design of in vitro assays to test for them. For example, beryllium produces negative results in the Ames assay, but is known to cause lung cancer in rodents and humans (19) . Thus, the rodent data acts as a safeguard against false negatives produced by in vitro assays and can be used by regulatory agencies to reduce or prevent human exposure to the suspect carcinogen.
Overall, the 2-year bioassay as practiced over the last 40 years has a remarkable sensitivity for detecting human carcinogens, both genotoxic and nongenotoxic (41) . The specificity of the 2-year rodent bioassay, however, has been controversial. Even the designers of the bioassay expected that testing one species would not be sufficient to detect all potential carcinogens, so they included both rats and mice. In agreement with this expectation, there is only 70% concordance between agents that are carcinogenic in mice and rats (83) . Similar concordance data is more difficult to generate between mice and humans, but it is assumed that a certain number of murine carcinogens will be noncarcinogenic in humans and vice versa. For example, ethanol is a known human carcinogen but evidence for carcinogenicity in mice is equivocal (8) .
The time, financial investment, and numbers of mice required for the two-year bioassay are substantial. The 2-year protocol significantly delays the introduction of critically needed pharmaceuticals to the public. A movement to validate new, more time-efficient (and therefore, less costly) models began in the early 1990s as an outgrowth of the ICH. In recent years, genetically engineered mouse models (GEMs) have begun to be evaluated for their potential to improve the timeliness, specificity and cost-effectiveness of carcinogen screening. Given the multistep nature of cancer, it is assumed that GEMs, which have already sustained at least 1 hit in the multistep process of tumorigenesis, will exhibit increased carcinogen sensitivity while decreasing the time required to evaluate suspect carcinogens. The four models that have received the most attention are the Tg.AC and rasH2 transgenic mice and p53+/− and XPA−/− knockout mice.
The Tg.AC mouse contains multiple copies of an activated form of the ras oncogene (31, 69) . The Tg.AC mouse is sensitive to skin papillomas and squamous cell carcinomas in response to topical application of skin tumor promoters, 355 356 PAYNE AND KEMP TOXICOLOGIC PATHOLOGY presumably because the initiating mutation in Ha-ras has been provided by the v-H-ras transgene (3, 64) . The transgene is not expressed in nontumor-bearing skin, but appears to be induced in response to full thickness wounding (2), ultraviolet irradiation (72) or chemical exposure (16, 63) . Nonetheless, specific and consistent housing and husbandry practices can effectively prevent false positive papillomas albeit at some additional cost per mouse (26) . Spontaneous skin papilloma incidence in untreated or negative control groups of singlehoused mice has been reported to be less than 4% (26, 35, 69) . The utility of the Tg.AC mouse, however, may be restricted to topical application of suspect carcinogens as oral gavage of chloroform failed to activate the v-H-ras transgene in the liver of treated mice (11) . The relevance of the Tg.AC mouse has been further confounded by a "nonresponder" phenotype identified in several studies (1, 71, 77) . The nonresponder phenotype is due to heritable genetic alterations within the transgene that lead to loss of transgene expression (27) . The Tg.AC transgene can be silenced by de novo deletions within palindromically oriented copies of the transgene sequence (27) , making the Tg.AC mouse a problematic choice for carcinogenicity studies.
The rasH2 transgenic mouse carries 5-6 copies of an overexpressed, but not activated, c-H-ras gene (55, 65) . The rasH2 transgenic mouse demonstrates increased sensitivity to genotoxic carcinogens, but its sensitivity to nongenotoxic carcinogens is equivocal (79) . Presumably, the enhanced susceptibility of the rasH2 transgenic mouse arises from activating mutation of the overexpressed transgene, but other interpretations are possible (65) .
Likewise, both the tumor suppressor gene p53+/− (22) and DNA repair gene XPA−/− (75) knockout mice are susceptible to genotoxic carcinogens as would be expected given the roles these genes play in response to DNA damage.
Overall, these GEMs exhibit increased specificity for the detection of genotoxic carcinogens as compared with the conventional 2-year bioassay using B6C3F1 mice, but the GEMs show inconsistent results with nongenotoxic carcinogens such as cyclosporin A, diethylstilbestrol, and estradiol (8) . Another major limitation of all GEMs evaluated to date is their reliance on the development of an increased incidence of tumors that also arise spontaneously in these strains. For example, both untreated and chemically exposed p53+/− mice develop primarily thymic lymphomas and sarcomas (8, 23, 37) . These tumor types have little direct relevance to the majority of human cancers. Thus, with respect to target organ specificity, extrapolation from GEMs to predict human cancer is severely limited (8) .
Recent results from our laboratory and others indicate that the p27 Kip1 (Cdkn1b tm1Mlfp ) knockout mouse may have substantial advantages for carcinogenicity screening compared with previously examined GEMs. The major advantage may be that p27 null mice are highly susceptible to carcinogeninduced tumors in a broad range of epithelial tissues. p27 AND TUMORIGENESIS The protein p27 (MW 27 kDa), also referred to as Kip1, was initially identified in complexes with cyclin E/CDK2 in cells that had been growth arrested with TGF-β, contact inhibition, or lovostatin (25, 51) . Interestingly, the activity of CDK2 was inhibited by the bound p27 indicating that p27 was a cyclin-dependent kinase inhibitor (CDKI). Subsequent studies demonstrated that other physiological agents that influenced cell proliferation such as cAMP, rapamycin and IFN-γ , also acted through p27 [reviewed in (50, 59, 60, 62) ]. As activation of cyclin-dependent kinases (CDKs) is at the core of cell cycle progression, p27 inhibition of CDKs suggested a direct connection between extracellular signals and cell cycle progression ( Figure 1 ). Quiescent cells generally have higher levels of p27 while proliferating cells downregulate p27. Enforced expression of p27 results in cell cycle arrest.
Over the past 5 years, a large number of studies from multiple laboratories have demonstrated the prognostic significance of p27 protein levels in human cancer ( Table 1 ). Reduction of p27 protein has been observed to varying degrees in all human malignancies examined to date [reviewed in (56, 74) ]. Decreased levels of total p27 protein are associated with high tumor grade and stage in human breast (4, 21) , colorectal (7, 57) and gastric cancer (81), among others. Reduction of p27 protein in tumors correlates significantly with decreased survival in breast (4, 53, 66) , colorectal (34), gastric (39), ovary (38, 42) , prostate (9), bladder transitional cell (10, 29) and esophageal squamous cell carcinoma patients (58) , among others. These global findings regarding p27 expression in human cancers are significant, as it is highly unusual for a single molecular marker to have strong prognostic value in such a wide array of tumor types. The evidence indicates that p27 plays a critical role as a tumor suppressor for multiple human epithelial cancers.
Three labs independently created p27 knockout mice and reported similar phenotypes (17, 32, 40) . p27−/− mice have an increased growth rate and adults are 20-30% larger than wild-type littermates. The increased size of the p27−/− animals is due to increased cellularity, as opposed to increased cell size, pointing to a key role of p27 in controlling growth in all tissue compartments in vivo. Interestingly, tissues from the p27+/− mice express roughly 50% the normal level of p27 protein and these mice show an intermediate growth rate. The intermediate phenotype of the heterozygous animals indicates that control of proliferation and even adult animal size is extremely sensitive to the levels of p27 protein. In addition, p27−/− mice exhibit hyperplasia of the pituitary intermediate lobe and nearly 100% of mice (on a 129/Sv genetic background) succumb as a result of benign pituitary adenomas by 1 year of age (53) (54) (55) . On a C57BL/6 background, pituitary tumor development is greatly delayed with only <10% incidence by 12 months of age (C. Kemp, unpublished observations). This indicates the existence of strain-specific modifiers of p27-induced pituitary tumor development. While other tumor types do occasionally develop in older p27 deficient mice (mostly between 18 and 24 months), these are not observed at increased incidence compared to wild-type controls (C. Kemp, unpublished observations).
However, when p27 null mice (on a mixed 129-C57BL/6 background) are challenged with either the point mutagen N-ethyl-N-nitrosurea (ENU), or the broad-spectrum mutagenic agent ionizing radiation, they show tumor predisposition in multiple tissues ( from >70 weeks in wild-type control mice to approximately 40 weeks in p27−/− mice (17) . In addition to reduced tumor-free survival, p27-deficient mice showed increased tumor multiplicity in diverse sites, with the majority of tumors deriving from epithelial tissues including small and large intestine, lung, ovary, and uterus (Table 2, Figure 2 ). p27-deficiency accelerates tumorigenesis in response to other classic chemical induction protocols, including 1,2dimethylhydrazine (DMH) induction of colorectal adenomas and adenocarcinomas (49), 7,12-dimethylbenz[a]anthracene For a detailed review, please see (61) .
(DMBA)/tetradecanoylphorbol-13-acetate (TPA) induction of papillomas and squamous cell carcinomas (48) and urethane induction of lung tumors (J. Philipp-Staheli and C. Kemp, unpublished results). For example, after subcutaneous injection of DMH for 12 weeks, colorectal tumor-free survival in p27−/− mice is significantly decreased as compared to wild-type mice. In the 2-stage skin carcinogenesis model, treatment of the dorsal skin of mice with a single dose of DMBA followed by repeated applications of the tumor promoter TPA results in benign papillomas that stochastically progress to malignant carcinomas. When skin tumors are induced in p27 nullizygous mice by this protocol, the p27-deficient mice show decreased tumor-free survival with an increase in both tumor size and malignant progression. One of the key disappointments of several GEM models is that they often succumb to sarcomas and lymphomas so rapidly as to obscure evaluation of possible roles in epithelially derived cancers, the leading cause of human cancer deaths. The susceptibility of the p27 knockout mouse to epithelially derived cancers is striking.
THE p27 KNOCKOUT MOUSE AS A MODEL
FOR CARCINOGENICITY SCREENING The p27 knockout mouse has several attributes that make it a promising candidate for carcinogenicity screening. First, the p27 knockout mouse is predisposed to tumors in a wide array of tissues when challenged with γ -irradiation or chemical carcinogens ( Table 2 and 
All neoplasms listed for γ -irradiation, ENU, urethane, and DMH show increased tumor incidence and/or increased tumor multiplicity in p27-deficient mice as compared to wildtype mice. DMBA/TPA treatment leads to ∼100% tumor incidence in wild-type mice in the experimental background. Thus, the only measurable effect of p27-deficiency in response to DMBA/TPA treatment was increased growth rate. with a single injection of ENU, p27-deficient mice develop adenomas and adenocarcinomas of the intestine and lung, as well as tumors of the adrenal gland, ovary, uterus, and pituitary at increased frequency in addition to the lymphoma and liver adenomas observed in wild-type mice (17) . When tumors are induced with a single injection of urethane, p27 knockout mice develop solid, papillary and mixed lung adenomas at increased frequency compared to wild type mice (J. Philipp-Staheli and C. Kemp, unpublished data). Clearly, unlike several genetically engineered mouse models under consideration for an improved rodent bioassay, the p27 knockout mouse has shown predisposition to a markedly broad spectrum of tumor types, particularly in epithelially derived tissues. Also, a positive result with the p27 knockout model is not reliant on detecting an increased incidence of spontaneously arising tumors, as the incidence of spontaneous tumors (other than pituitary adenomas) is low.
Second, p27-deficiency cooperates with multiple oncogenic mutations in both oncogenes and tumor suppressor genes, including those in the Hras oncogene, the retinoblastoma gene (Rb), and the p18 INK4c , PTEN, and adenomatous polyposis coli (Apc) tumor suppressor genes (13, 20, 46, 48, 49) . As mentioned previously, p27-deficiency increases both tumor size and malignant progression in the two-stage skin carcinogenesis protocol in which an activating mutation of Hras is the initiating lesion. In Rb+/− p27−/− compound mutant mice, pituitary and thyroid C cell tumorigenesis is accelerated, while pituitary tumorigenesis is accelerated in p18 INK4c −/− p27−/− compound mutant mice. Both the penetrance and invasiveness of prostatic intraepithelial neoplasia were accelerated in PTEN+/−p27−/− mice relative to PTEN+/− mice. Tumor-free survival was decreased and tumor multiplicity was markedly increased in Apc Min /+p27−/− mice relative to Apc Min /+ mice. Further, in combination with transgenic mice expressing human growth hormone-releasing hormone, p27-deficient mice show earlier appearance and increased penetrance of pituitary tumors (67) . Thus, p27 inhibits tumor growth in response to multiple oncogenic signals and in multiple tissues. Chronic carcinogen exposure, such as would occur in the carcinogen bioassay, would likely produce mutations in a variety of oncogenes and tumor suppressor genes. The highly cooperative nature of p27 suggests the p27−/− mouse will accelerate tumorigenesis resulting from multiple carcinogenic pathways, thereby increasing the sensitivity of and decreasing the time required for the rodent bioassay.
A notable exception is the Smad3−/− mouse, which spontaneously develops adenomas and adenocarcinomas of the large intestine (84) . p27-deficiency does not accelerate morbidity, tumor multiplicity, or tumor size in Smad3−/− mice (49) . Interestingly, unlike those oncogenic mutations with which p27 cooperates, mutations of Smad3 are rare in human cancers (1, 43, 76) .
Third, the p27 knockout mouse, unlike mouse models with knockouts of genes involved in responding to or repairing DNA damage, is likely to detect both genotoxic and nongenotoxic carcinogens. The p53+/− mouse, for example, is susceptible to tumor induction by a variety of genotoxic agents such as benzene and p-cresidine (22) . However, the p53+/− mouse shows only a marginal increase in susceptibility with a correspondingly marginal decrease in latency in response to nongenotoxic agents such as beryllium (19, 68) . The diversity of physiologic and exogenous signals that impinge and act upon p27, and the divergent array of human tumors that show alterations in p27 expression suggest that p27 may be involved in yet more pathways. If p27 plays a key role in cell fate decisions as accumulating data suggest (5, 12) , then p27 levels could be a major rate-limiting factor for tumor progression. It is therefore likely that the p27 knockout mouse will respond to a variety of chemical carcinogens acting through a diverse array of mechanisms and pathways. It has been demonstrated that the p27 knockout mouse responds to at least 1 nongenotoxic cocarcinogen, the tumor promoter TPA (48) . The available evidence suggests that reduction of p27 protein leads to increased cell proliferation and increased growth rate of tumors (49) . Many nongenotoxic carcinogens may act by increasing cell proliferation. Therefore, p27-deficiency may detect this class of carcinogens with increased sensitivity. Indeed, TPA seems to act as a cocarcinogen in part by downregulating p27, leading to increased cell proliferation. Fourth, p27 is haploinsufficient for tumor suppression, indicating a clear effect of p27 (Cdkn1b) gene dosage (17) . The gene dosage sensitivity of the p27 knockout mouse lends itself to the usage of both p27+/− and p27−/− mice in the bioassay if indicated. This would be especially useful for testing chemicals with equivocal or controversial carcinogenicity. In these cases, the intermediate sensitivity of the p27+/− mice will increase confidence in the results and will increase the statistical power of the study.
Fifth, use of the p27 knockout mouse in carcinogenicity screening will likely lead to a substantial decrease in the time required to conduct the rodent bioassay, and as a result, the financial investment will decrease significantly. Treatment of p27 knockout mice with ENU resulted in 100% tumor-associated mortality by 40 to 50 weeks of age while γ -irradiation resulted in 100% mortality of p27 knockout mice by 40 weeks of age as compared to only 50% by 70 weeks in wild-type mice (17) .
PRACTICAL CONSIDERATIONS
The conventional 2-year rodent bioassay is conducted on the F1 offspring of female C57BL/6 mice crossed to male C3H/He mice. The use of B6C3F1 mice is not rooted in biology so much as in historical precedent. The continued use of B6C3F1 mice, however, is desirable given the vast quantity of data that has been generated on this precise genetic background over the years. The Cdkn1b tm1Mlfp p27 knockout allele was initially generated on a mixed 129/Sv and C57BL/6 background (18) . Our lab has created congenic lines of both C3H/He p27−/− and C57BL/6 p27−/− mice by backcrossing the p27 knockout allele onto both backgrounds. By crossing C57BL/6 p27+/− mice to C3H/He p27+/− mice, B6C3F1 p27+/+, p27+/− and p27−/− mice can be readily generated in order to analyze the effect of p27-deficiency on this background. A potential disadvantage of the B6C3F1 background is the high background liver tumor incidence, which may be intensified by the accelerated growth characteristics of p27-deficient mice. In our experience, however, p27-deficient mice do not develop liver tumors at greater incidence than wild-type C3H/He mice over a study period of one year (S. Payne and C. Kemp, unpublished data). Hence, one of the difficulties with using transgenic animals in carcinogenicity screening, due to unknown genetic background effects, may be circumvented in the p27 knockout mouse.
What experiments need to be done to validate the p27 knockout mouse for carcinogenicity screening? In recent years, the framework for evaluation of GEMs has begun to be developed under the initiative of the International Life Sciences Institute (ILSI) Alternatives to Carcinogenicity Testing (ACT) program (52) . Although much work has been done to standardize the generation, evaluation and presentation of data from multiple laboratories, much work remains. Importantly, there is a need for agreement on standard strain choice, standard exposure period, optimal sample size and a standard list of calibration chemicals. The following are our recommendations for preliminary evaluation of the p27 knockout mouse as a model for carcinogenicity testing.
First, researchers will need to generate the B6C3F1 p27−/− mouse and evaluate the phenotype in order to confirm that it does not deviate dramatically from the phenotype of either the C57BL/6 p27−/− or C3H/He p27−/− mouse. The B6C3F1 p27−/− mouse should be carefully monitored for spontaneous tumor susceptibility.
Additionally, the length of chemical exposure will need to be determined. In experiments with the p53+/− mouse, an exposure time of 20-26 weeks has proved sufficient. Given that exposure to a single dose of γ -irradiation or ENU resulted in tumor-induced mortality in the p27−/− mouse by 40 weeks of age, 20-26 weeks may prove to be a sufficient length of exposure for the p27−/− mouse as well. Duration of exposure is most critical in studies in which the test chemical does not induce tumors or only weakly so. Under those circumstances, an exposure in excess of 26 weeks may be required to determine the carcinogenicity of the chemical. The C57BL/6 p27 knockout mouse should be able to provide credible information with exposures as long as 60 weeks.
Finally a battery of chemicals whose carcinogenicity status is known will need to be tested on the B6C3F1 p27−/− mouse in order to confirm both the sensitivity and the specificity of the p27 knockout mouse model. Genotoxic (eg, cyclophosphamide, melphalan, phenacetin), and nongenotoxic (eg, diethystilbestrol, estradiol) carcinogens as well as human noncarcinogens (eg, phenobarbitol, clofibrate, reserpine, haloperidol, chlorpromazine) should be tested. The 21 compounds selected for testing by the ILSI ACT program should serve as a basis to guide initial carcinogenicity testing (54) . It will be particularly interesting to test chemical compounds that yield equivocal results in the 2-year rodent bioassay in the B6C3F1 p27−/− mouse in order to determine whether the p27 knockout mouse yields less equivocal results.
In short, the p27 knockout mouse exhibits broad tissue susceptibility to neoplasia, in combination with a reduced time to tumor development. The central role of p27 in cell cycle regulation and in responding to endogenous and exogenous proliferative stimuli indicate that p27-deficiency, unlike the GEM models currently under consideration, will likely detect nongenotoxic carcinogens with increased sensitivity, in addition to genotoxic carcinogens. Further, the intermediate susceptibility of p27 heterozygous mice enhances the capacity of p27-deficient mice to discriminate between weak carcinogens and noncarcinogens. Finally, the susceptibility of the p27 knockout mouse to epithelially derived tumors and its cooperation with a variety of oncogenic mutations that occur frequently in human cancers is a strong argument for the relevance of the p27 knockout mouse model for carcinogenicity screening of potential human carcinogens. Experimental evaluation of the p27 knockout mouse as a model for carcinogenicity screening is clearly warranted.
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